This increased thyroid cancer risk remained higher until 60 months after the index CMM, which could suggest the involvement of cancer-promoting genetic abnormalities (i.e., BRAFv600e, CDKN2A) which could potentially be involved in the pathogenesis of both malignancies (23–26). The gene discussed is CDKN2A; the disease is thyroid cancer.